There are currently 633 clinical trials in Charleston, South Carolina looking for participants to engage in research studies. Trials are conducted at various facilities, including Medical University of South Carolina, GSK Investigational Site, Hollings Cancer Center at Medical University of South Carolina and Medical University of South Carolina (MUSC). Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Recruiting
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: Medical University of South Carolina, Hollings Cancer Center, Charleston, South Carolina
Conditions: Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung, EGFR Amplification, Epithelial Ovarian Cancer, Pancreas Cancer, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Squamous Cell Carcinoma of Head and Neck
A Study to Evaluate the Safety of CMTX-101 in People with Cystic Fibrosis
Recruiting
CMTX-101 is a bacterial biofilm disrupting monoclonal antibody being developed as an adjunctive therapy to standard of care antibiotics. The goal of this clinical trial is to assess the safety and tolerability of CMTX-101 in people with cystic fibrosis (pwCF). The main questions the study aims to answer are: * Are single doses of CMTX-101 IV infusion safe and tolerated * What is the pharmacokinetic (PK) profile of single doses of CMTX-101 * Do single doses of CMTX-101 induce development of ant... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Persistent Infection, Cystic Fibrosis
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
Recruiting
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: MUSC Health, Charleston, South Carolina
Conditions: Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
Gene Therapy for ACM Due to a PKP2 Pathogenic Variant
Recruiting
This is a Phase 1/2, first-in-human, open-label, intravenous, dose-escalating, multicenter trial that is designed to assess the safety and tolerability of LX2020 in adult patients with PKP2-ACM
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/22/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Arrhythmogenic Cardiomyopathy, PKP2-ACM, PKP2-ARVC
Anesthetics and Analgesics in Children
Recruiting
The purpose of this study is to characterize the pharmacokinetic (PK) and safety profile of anesthetics and analgesics in children and adolescents.
Gender:
ALL
Ages:
Between 0 years and 17 years
Trial Updated:
01/21/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Anesthesia, Pain
Modulating Anxious Coping
Recruiting
This is a study to find out if a device that temporarily alters brain activity (repetitive transcranial magnetic stimulation, rTMS) might be used to change how people with anxiety or related concerns cope with feared or anxiety-producing situations. The study is recruiting people who recently started treatment for anxiety or a related concern. The study involves 3 visits to the Medical University of South Carolina. At the first visit, participants do interviews and surveys asking about anxiety a... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/21/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Anxiety Disorders
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study
Recruiting
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread to other places in the body (metastatic). Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
Posterior Wall Substrate Modification Using Irreversible Electroporation for Paroxysmal Atrial Fibrillation
Recruiting
The purpose of this study is to compare the efficacy and safety between pulmonary vein isolation (PVI) alone versus PVI with left atrial (LA) posterior wall isolation (PWI) using pulsed-field ablation (PFA) in the treatment of patients with paroxysmal atrial fibrillation (PAF).
Gender:
ALL
Ages:
Between 21 years and 90 years
Trial Updated:
01/21/2025
Locations: Trident Medical Center, Charleston, South Carolina
Conditions: Atrial Fibrillation Paroxysmal
Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
Recruiting
SUSTAIN (Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with excessive sleepiness associated with shift work disorder (SWD).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/21/2025
Locations: Clinical Research Site, Charleston, South Carolina
Conditions: Excessive Sleepiness, Shift-work Disorder
Intravesical BCG vs GEMDOCE in NMIBC
Recruiting
The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a non-inferior event-free survival (EFS) compared to standard treatment with intravesical BCG. The purpose of this study is to test whether Gemcitabine + Docetaxel is a better or worse treatment than the usual BCG therapy approach. The primary objective of this study is to determine the event free survival (EFS) of BCG-naïve high gr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/20/2025
Locations: Ralph H Johnson VA Medical Center, Charleston, South Carolina +1 locations
Conditions: Non-muscle-invasive Bladder Cancer
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
Recruiting
This study is enrolling participants who are already implanted with a S-ICD device ( subcutaneous ICD), and are undergoing a routine outpatient clinic follow up appointment to have their S-ICD checked. The aim of the study is to see if a feature in the device can recognize muscle movement and differentiate movement from irregular heart signals. The study involves doing some simple arm exercises while collecting device data, both with this feature turn on and then with it turned off. Participants... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/19/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Subcutaneous ICD, Myopotential Interference
Low-Intensity Focused Ultrasound for Treatment-Resistant Depression
Recruiting
The Investigators are proposing to demonstrate safety and efficacy of LIFUP for treatment resistant major depressive disorder in a ten-patient pilot study. LIFUP is an emerging treatment with the advantage of being able to target subcortical transcranial targets, which may have superior efficacy or a shorter treatment course compared to other available treatments such as transcranial magnetic stimulation. This study will investigate the effect of this stimulation on the left subgenual cingulate... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
01/17/2025
Locations: 30 Bee Street, Charleston, South Carolina
Conditions: Major Depressive Disorder, Treatment Resistant Depression